Novavax Reports Results of NVX-CoV2373 in Pediatric Population of P-III (PREVENT-19) Trial for the Treatment of COVID-19
Shots:
- The pediatric expansion of the P-III (PREVENT-19) trial evaluates NVX-CoV2373 vs PBO in a ratio (2:1) in 2247 adolescents aged 12 through 17yrs. with COVID-19 at 73 sites in the US
- The results showed that patients achieved primary effectiveness EPs with neutralizing Ab responses non-inferior to those observed in young-adult, 82% clinical efficacy against Delta variant, immune responses were 2 to 3 fold higher in adolescents than adults, was well-tolerated & no safety signals were observed
- The company is planning to submit the regulatory filings in Q1’22 & will initiate an additional study globally for younger patients in Q2’22. The vaccine is currently under multiple regulatory agencies’ review
Ref: Businesswire | Image: Novavax
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com